Men should also take HPV vaccine: Experts
Health experts said that males can spread human papillomavirus (HPV) to their female partners and are also at risk. While HPV is often associated with cervical cancer in women, it also causes several serious diseases in men, including penile cancer, anal cancer, and oropharyngeal cancer as well as genital warts.
Panel of medical specialists took part in discussion on public health implications of HPV at the 'Conquer HPV & Cancer Conclave 2025' organised by the Serum Institute of India (SII). They advised routine screening tests to detect HPV-related disease early in girls. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential.
'Through these conclaves held across the country, we aim to increase understanding of HPV and its link to cervical and other cancers,' said Parag Deshmukh, executive director, SII.
Experts said vaccinating boys and girls at young age can help strengthen their immune systems before they are exposed to the HPV virus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
6 hours ago
- Economic Times
Wockhardt activates Zaynich push, eyes global licensing deals
Habil Khorakiwala Mumbai: Wockhardt is working on ambitious plans for Zaynich, a combination of zidebactam and cefepime that was found to be effective during clinical trials to fight superbugs or bacterial infections that show resistance to a range of existing antibiotic treatments. The drug maker has hired merchant bankers to identify possible out-licensing deals for the novel product, chairman Habil Khorakiwala told ET in an exclusive interview. Wockhardt in March sought regulatory approval for Zaynich in India and expects its commercial launch in the first half of '26. In the US, it plans to file for regulatory clearance in August.'We will get into the US market by the end of FY26 or latest by the second half of 2026 and Europe will be a year later,' Khorakiwala said. Zaynich is seen as a game-changing drug against drug-resistant gram-negative pathogens. These pathogens are difficult to kill. Zaynich is estimated to have a market opportunity of about $9 billion. Around a million people die due to multidrug resistance in India every year, while worldwide, the number is 5 million, Khorakiwala said. Currently there are very few effective treatments available for these infections. Mumbai-based Wockhardt completed the Phase-3 clinical trials for Zaynich earlier this year. In January it announced that the drug demonstrated more than 97% clinical efficacy in treating serious infections of bacteria resistant to carbapenem antibiotics, which are often used as a last resort to treat severe infections. The company is prepared to go solo to market Zaynich in India, the US and other markets if the licensing proposals do not meet its expectations on valuation, Khorakiwala said without revealing the valuation he is looking for.'We will evaluate how to go about and take an appropriate call, so we are keeping two options fully alive,' Khorakiwala said. 'One option is licensing out, the other is in some markets like in India we are doing ourselves,' he said. 'The US is another market where we are thinking of the possibility (of marketing on its own); you don't need too much marketing cost and you have talent available.'Wockhardt also plans to fully outsource manufacturing for the Western markets to eliminate issues related to the US Food and Drug Administration, and channel its focus on the clinical and research part.'For manufacturing, plenty of options are available in Europe and the US, so I am not getting into FDA-related manufacturing problems,' said Khorakiwala. 'Zaynich — we are manufacturing everything in Europe.' It will adopt the same strategy to outsource most of the manufacturing for all its other new company had in the past faced some issues with the US FDA over alleged violations of good manufacturing practices. 'That (FDA-elated manufacturing problems) was our weakness, and I am eliminating that completely from my western markets to only focus on the clinical and research part,' he said. COMPANY TURNAROUND Wockhardt has seen a remarkable turnaround in its stock price in the past year and a half with renewed confidence from investors, with developments on Zaynich being among the key drivers. Its stock price more than doubled in the last 12 months and increased over three-and-a-half times since January 2024. The shares closed at `1,713.20, up 4.5%, on BSE Monday. 'We have revisited what are the strengths and what are the opportunities — one obviously is our new drug discovery — in India and worldwide,' said also stressed on the company's focus on biologics as another key growth driver.'Within biologics we will stay in insulin and GLP1; we are not going to touch the rest of the biologics like monoclonal antibodies and others. Because we feel it is important to be focused,' he does not see itself as a generic company, he said. 'In fact, in the US we are exiting generics … we will be focused on the biological area and NCE (new chemical entities) and strictly on antibiotics,' he chairman said his research pipeline has a range of antibiotics under development, including early-stage work on an oral version of Zaynich. PRICING STRATEGY Khorakiwala said the treatment cost with most new products including antimicrobials launched in the last 10 years in the US has been in the range of $10,000-15,000 per treatment. Zaynich will also hover in that range in the US but in India, the price will be significantly lower, he said.
Time of India
12 hours ago
- Time of India
Series of sudden heart-related deaths in Karnataka prompts study
Bengaluru/Mysuru: A series of sudden deaths attributed to cardiac ailments among individuals under 40 in Karnataka has prompted urgent investigations by both the state govt and cardiologists' bodies in Hassan and Mysuru. At least 18 deaths reported over a one-month period in Hassan are now being formally investigated by a committee headed by Dr K S Ravindranath, director, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, in collaboration with Hassan Institute of Medical Sciences (HIMS). The committee's report is to be submitted within 10 days. Chief minister Siddaramaiah said the govt will verify deaths and take appropriate action. You Can Also Check: Bengaluru AQI | Weather in Bengaluru | Bank Holidays in Bengaluru | Public Holidays in Bengaluru Dr Rajanna B, the HIMS director, confirmed that the deaths being reviewed had occurred between May 28 and June 28, 2025. "Fourteen of the deceased died at home without consulting doctors. Around nine people were aged under 30, while most others were above 50," he said. With many of the deaths having occurred too long ago for a post-mortem, investigators are primarily relying on medical histories and accounts from local doctors and families. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 6 dias no Reino da Magia Azul Linhas Aéreas Compre já Undo Dr KS Sadananda, superintendent of Jayadeva Mysuru, said: "We now see 3-4 young patients suffering heart attacks daily — many with no prior symptoms." Earlier, admissions were largely limited to those with known conditions such as hypertension, diabetes, obesity, or smoking habits. Harsh Gupta, the health and family welfare principal secretary said the committee — previously convened for Covid-related reviews — has now been tasked with investigating these deaths. The sudden surge in cardiac fatalities has triggered public anxiety. "Emergency OPDs at Jayadeva hospitals in Bengaluru and Mysuru have seen a 20% spike in footfall, while 200-300 additional outpatients each in Bengaluru and Mysuru were seen in general OPD on Monday," Dr Ravindranath said. At the same time, the Mysuru chapter of the Cardiological Society of India (CSI) has initiated a region-wide study on rising cardiac cases among young people. Under the supervision of CSI Mysuru president Dr Shashirekha and secretary Dr Veena Nanjappa, the study aims to collect data over two years and submit preventive recommendations to the state govt. The data will cover patients admitted to Jayadeva as well as private hospitals such as Narayana Hrudayalaya, Manipal, BGS Apollo, and others. BOX: Not A New Trend: CN Manjunath Noted cardiologist and Bangalore Rural MP Dr C N Manjunath dismissed rising cases of cardiac fatalities as a new trend. "For two decades, the young and middle-aged are vulnerable to heart attacks and related complications. Between 2013 and 2018, when I was the director at Jayadeva, Bengaluru, we studied 5,000 young heart attack patients. Among those between 20 and 45 years old, 50% were smokers, 18-20% had diabetes and high BP, 17% had a strong family history of premature heart attack," he said. The worrying aspect, he said, was that 25% of the patients were without conventional risk factors, adding that the food safety department should start looking at pesticide residues in fruit and vegetables.
The Hindu
14 hours ago
- The Hindu
Biological E. to produce Jiangsu Recbio Tech's HPV9 vaccine REC603
Hyderabad-based vaccine maker Biological E. will produce Chinese biopharmaceutical firm Jiangsu Recbio Technology Company's recombinant 9-valent HPV (HPV9) vaccine REC603 under a licensing cooperation agreement the companies announced on Monday. The Hong Kong stock exchange listed Recbio, under the agreement, will provide BE with drug substance (DS) and transfer technology to formulate, fill and package the vaccines. Technology transfer for the DS production will be given at an appropriate time in future, the companies said in a release. BE will receive exclusive right to commercialise the vaccine in India and participate in UNICEF and PAHO tenders in other markets. It will begin large-scale manufacturing of the HPV9 vaccine once the technology transfer is completed. The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal and oropharyngeal cancers as well as genital warts. Following the license agreement, Recbio has started transferring necessary technical knowledge, materials and expertise to BE for producing the vaccine. It will continue to support BE in clinical development and regulatory approvals. Their collaboration comes at a time when the global demand for cervical cancer prevention is at an all-time high. By leveraging BE's advanced manufacturing capabilities, their partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets, the companies said. 'This cooperation is another significant progress for Recbio in expanding into international markets., We will work together with our Indian partner to accelerate the launch process of the HPV9 vaccine in India and jointly make greater contributions to global public health,' Founder, Chairman and CEO of Recbio Liu Yong said. The Chinese firm has a portfolio of at least 10 high-value innovative vaccines covering major disease areas such as cervical cancer, herpes zoster and respiratory syncytial virus. REC603, one of its core products, is for people aged 9-45 years and currently in the phase III clinical trials in China. BE Managing Director Mahima Datla the company and Recbio are committed to ensure the life-saving vaccine is delivered to those who need it the most.
